Rick Shimkets

Richard Shimkets, a seasoned professional in the biotechnology industry, currently holds the position of SVP Genetics and New Technologies at Alloy Therapeutics, Inc. Richard is also CEO of Daedamab, a subsidiary of Alloy Therapeutics. With extensive experience as President and CEO of Abeome Corporation and VP Drug Discovery at CuraGen Corporation, Richard has a strong background in genetics and a solid educational foundation with a PhD from Yale University and a BS from The University of Georgia.